A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)
Phase of Trial: Phase II/III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Intepirdine (Primary)
- Indications Dementia; Lewy body disease
- Focus Adverse reactions
- Acronyms HEADWAY-DLB Extension
- Sponsors Axovant Sciences
- 13 Feb 2018 Status changed from recruiting to discontinued.
- 28 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.
- 28 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2018.